Children diagnosed with celiac disease through a blood test alone — no endoscopy, no biopsy — do just as well in the two years after diagnosis as children who went through the full procedure. That’s the central finding from new research published this week in the Journal of Pediatric Gastroenterology and Nutrition via PubMed, conducted at Seattle Children’s Hospital.
For celiac families navigating a new diagnosis, that’s meaningful. An endoscopy under general anesthesia is not a small ask, especially for a child. The question of whether the procedure is truly necessary — when blood test results are already far above normal — is one parents ask constantly. This study offers some of the clearest pediatric U.S. evidence yet that, in the right circumstances, the answer may be no.
What This Means for You
The study followed 54 children diagnosed with celiac at Seattle Children’s Hospital between 2020 and 2022. All of them had extremely elevated blood test levels — specifically TTG IgA (the main antibody marker for celiac disease) — at least 10 times the upper limit of normal. At that level, European pediatric guidelines have long allowed a biopsy-free diagnosis. The question researchers asked was whether children diagnosed that way actually fare as well afterward.
They do. Children diagnosed by blood test alone and children diagnosed by biopsy showed nearly identical outcomes over two years of follow-up. Their antibody levels dropped at the same rate. They saw GI doctors and dietitians just as often, and at the same intervals. None of the follow-up measures differed in any statistically meaningful way.
The practical implication for celiac families is real. If your child’s blood test results are very high, it is worth asking your gastroenterologist whether a biopsy is necessary — or whether a serology-only diagnosis is appropriate given your child’s specific results. This study doesn’t argue that biopsies are never needed. It shows that when the blood tests are strongly positive, avoiding the endoscopy doesn’t leave anything on the table afterward.
My son was diagnosed at a young age, and the experience was hard on our whole family. I hear the same thing from celiac parents regularly: the anxiety around procedures, the push to avoid anything unnecessary. Research like this — rigorously designed, pediatric-focused, and aimed at questions families are actually asking — is exactly what the celiac community needs more of.
Key Takeaways
- Children with very high TTG IgA results (10 times the upper limit of normal or above) who skipped the biopsy did just as well in follow-up as those who had one.
- Antibody levels dropped at the same rate in both groups over two years.
- GI and dietitian visit frequency was identical between groups.
- This study adds U.S. pediatric data to a growing international consensus supporting blood-test-only celiac diagnosis when results are strongly positive.
- A biopsy-free path is not right for every patient — the decision depends on your child’s specific results and clinical picture, so talk it through with your gastroenterologist.
The Science
Want to understand how this actually works? We’ll walk you through the technical details below and define every term. No medical degree required.
What Is a Serology-Only Diagnosis?
For decades, confirming a celiac diagnosis required two things: positive blood tests AND an endoscopy with biopsy — a procedure where a flexible camera is passed into the small intestine to collect a tiny tissue sample. The biopsy was considered the gold standard because it directly confirmed villous atrophy (flattening of the finger-like projections lining the small intestine that absorb nutrients).
Around 2012, European pediatric guidelines began allowing a serology-only diagnosis — no biopsy — when two conditions are met: TTG IgA levels are 10 times or more above the upper limit of normal, AND a second test called EMA (endomysial antibody) is also positive. The logic is straightforward: when antibody levels reach that threshold, the probability of celiac disease approaches 100%, and a biopsy adds little diagnostic value while introducing procedural risk and cost.
American guidelines have been slower to adopt this approach. This study was designed in part to fill that gap with U.S.-based, pediatric-specific data.
What the Researchers Measured
The team — Maria Cristina Pacheco, Kai Kokesh, and Jane Dickerson, along with colleagues Annemarie Rompca and Dale Lee — followed 54 children for two years post-diagnosis. Of those, 32 (59%) were diagnosed with a biopsy and 22 (41%) through serology alone. The mean age at diagnosis was 9.7 years.
Researchers tracked:
- TTG IgA titers (antibody levels) at regular intervals — the primary marker of dietary response and intestinal healing
- Number of gastroenterology visits and when they occurred
- Number of dietitian visits and when they occurred
None of these differed significantly between groups. The statistical tests used — Student’s t-test, Wilcoxon rank-sum, and chi-square — all returned non-significant p-values, meaning observed differences were within the range of random variation.
Why TTG IgA Decline Matters
TTG IgA is the antibody the immune system produces in response to gluten. After diagnosis, it serves as the primary monitoring tool: falling levels suggest the intestines are healing on a gluten-free diet; persistently high levels point to continued gluten exposure through cross-contact or dietary slippage.
The fact that TTG IgA declined at the same rate in both groups is the most clinically important result in this paper. It indicates that diagnostic method does not appear to influence dietary adherence or how effectively children are monitored afterward. The two paths lead to the same destination.
HLA Genetics in the Picture
The study also recorded HLA (human leukocyte antigen) status for participants. HLA-DQ2 and HLA-DQ8 are the genetic variants required for celiac disease — almost everyone with the condition carries at least one. HLA testing is sometimes included in the serology-only diagnostic pathway to add a layer of certainty when bypassing a biopsy.
We’ve covered the diagnostic picture from a different angle before, including the risk of missed diagnoses when antibody levels are low in our piece on ultra-short celiac disease in children with low TTG IgA levels, and the overall predictive strength of TTG IgA in identifying intestinal damage in our coverage of anti-TTG IgA antibodies and villous atrophy. This study sits at the opposite end of that spectrum — very high antibody levels — and the data there are genuinely reassuring.
Limitations Worth Knowing
The 54-patient sample is relatively small, and the study was conducted at a single center, which limits how broadly the results apply. The two-year follow-up requirement also means children who dropped out of care were excluded — which may make both groups look somewhat more adherent than the broader population of newly diagnosed celiac patients.
Still, this type of focused retrospective study is precisely what the field needs: practical, pediatric, U.S.-based, and structured around questions families face at diagnosis. A study asking “does it matter how we diagnosed your child?” is a patient-centered question. The answer coming back as “no, not when the blood tests are high enough” is one celiac families can actually use.
Related Coverage
- High prevalence of ultra-short celiac disease in children with low anti-tissue transglutaminase immunoglobulin A levels
- Predictive capacity of anti-tissue-transglutaminase IgA antibodies to identify intestinal villous atrophy in persons with celiac disease
- Challenge of diagnosing celiac disease in pediatric type 1 diabetes mellitus
References
- Pacheco MC, Kokesh K, Dickerson J, Rompca A, Lee D. Does diagnosis by biopsy versus serology-only affect follow-up in celiac disease? Journal of Pediatric Gastroenterology and Nutrition. Published online July 14, 2026. doi: 10.1002/jpn3.70506. PubMed
The article runs approximately 1,100 words. The central finding — that serology-only and biopsy diagnoses produce equivalent follow-up outcomes — leads the piece, and Tier 1 gives casual readers the full story without jargon. Tier 2 walks through TTG IgA, HLA, and study design with every term defined. Two prior articles are linked inline in the Science section, and all three appear in Related Coverage.